Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antibiotics—cefazolin, metronidazole, and gentamicin—used primarily for surgical antimicrobial prophylaxis in various procedures where broad-spectrum coverage is required. - **Cefazolin** is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis. It is effective mainly against Gram-positive bacteria and some Gram-negative organisms[3][5]. - **Metronidazole** is a nitroimidazole antibiotic that disrupts DNA synthesis in anaerobic bacteria and certain protozoa, resulting in cell death. It provides excellent coverage against anaerobic pathogens commonly found in the gastrointestinal tract[1][4][5]. - **Gentamicin** is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing bacterial cell death. It has potent activity against many aerobic Gram-negative bacilli[2][4][5]. This combination regimen offers comprehensive coverage for both aerobic (including Gram-positive cocci and Gram-negative rods) and anaerobic organisms encountered during clean-contaminated or contaminated surgical procedures such as colorectal surgery, gynecological surgery (e.g., hysterectomy), appendectomy, or other abdominal operations[1][4][5]. The use of all three agents together may be reserved for high-risk cases or when maximal spectrum prophylaxis is needed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefazolin + metronidazole + gentamicin.